Merck Serono's easypod HGH injection device approved in Japan
This article was originally published in Scrip
Merck Serono's electronic autoinjection device, easypod, has been approved for use with its recombinant human growth hormone, Saizen (somatropin), in Japan. The easypod device allows patients to self-inject in three steps, with the needle being hidden during the injection process. It can also deliver a preset dose and automatically record the number of doses administered, allowing physicians to check patient adherence. The device was made available in the US and a number of European countries in 2007, and is now approved in 40 countries, including the US and those in the EU.
You may also be interested in...
The European Commission has extended the indications for Janssen’s Tremfya to include psoriatic arthritis, and those for BMS’s Opdivo to include gastroesophageal cancer.
Denmark’s biotech Genmab has dropped the AXL targeted antibody-drug conjugate, enapotamab vedotin from early clinical development, and is focusing its resources on other therapeutic programs.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.